Xspray Pharma publishes prospectus in connection with its listing on Nasdaq Stockholm

Regulatory press release 2020-03-23

STOCKHOLM – March 23, 2020. Xspray Pharma AB (Nasdaq First North Growth Market: XSPRAY) announced on March 18, 2020 that Nasdaq Stockholm’s listing committee had approved that the company’s shares are admitted to trading on Nasdaq Stockholm’s main market. Today, on 23 March, the prospectus that has been prepared by the company in connection with the listing was approved and registered by the Swedish Financial Supervisory Authority (“SFSA”) and is now available on Xspray Pharma’s website, www.xspraypharma.com, and on SFSA’s website, www.fi.se. 

The first day of trading on Nasdaq Stockholm’s main market is 27 March 2020. The last day of trading on Nasdaq First North Growth Market is 26 March 2020. Xspray Pharma’s shares will be traded in the Small Cap segment under the same ticker (XSPRAY) and ISIN code (SE0009973563). No new shares will be issued in connection with the listing. Shareholders of Xspray Pharma do not need to take any action in connection with the listing on Nasdaq Stockholm Main Market.


For further information, please contact:

Per Andersson, CEO, Xspray Pharma AB

Phone: +46 (0) 706 88 23 48

E-mail: per.andersson@xspray.com



The information was sent for publication, through the agency of the contact person set out above, on March 23, 2020, at 17:30 CET.


About Xspray Pharma

Xspray Pharma AB (publ) is a product development company with multiple product candidates in clinical development. Xspray uses its innovative, patented RightSize technology to develop improved and generic versions of marketed drugs, primarily protein kinase inhibitors (PKIs) for the treatment of cancer. The segment is the second largest in oncology, and drug prices are very high.

The company´s innovative technology allows Xspray Pharma to gain entry as the first competitor to today’s original drugs before the secondary patents expire. Xspray’s goal is to become the leader in the development of improved drugs or generic versions of PKIs already marketed for the treatment of cancer, which numbered to 54 in December 2019. The company’s leading product candidates, HyNap-Dasa, HyNap-Sora and HyNap-Nilo, are stable amorphous versions of the three blockbuster cancer drugs Sprycel® (dasatinib), Nexavar® (sorafenib) and Tasigna® (nilotinib), respectively. The launch of the first product candidate, HyNap-Dasa, is planned to take place in 2021. The substance patent for the original drug Sprycel® (dasatinib) expires at the end of 2020, and the secondary patents in 2026, which offers Xspray’s HyNap-Dasa a period of five years of semi-exclusivity before other competitors gain access to the market.

The company has patented manufacturing technology, equipment and the resulting products. The shares in Xspray Pharma are traded on Nasdaq First North Growth Market Stockholm.



Redeye AB is Xspray Pharma’s Certified Adviser


+46 (0) 8 121 576 90